Scarica l'app Stockscreener
1.12
1.75%
-0.02
Dopo l'orario di chiusura:
1.15
0.03
+2.68%
Fate Therapeutics Inc Borsa (FATE) Ultime notizie
Institutional owners may take dramatic actions as Fate Therapeutics, Inc.'s (NASDAQ:FATE) recent 20% drop adds to one-year losses - simplywall.st
Fate Therapeutics’ SWOT analysis: promising data boosts stock outlook - Investing.com
TC Biopharm (NASDAQ:TCBP) versus Fate Therapeutics (NASDAQ:FATE) Critical Review - Defense World
Fate Therapeutics (NASDAQ:FATE) Given “Hold” Rating at Needham & Company LLC - Defense World
FATE: Analyst Maintains Hold Rating on Fate Therapeutics | FATE Stock News - GuruFocus
Needham maintains hold on Fate Therapeutics stock despite lupus data By Investing.com - Investing.com Canada
Why Is Fate Therapeutics (FATE) Up 61.5% Since Last Earnings Report? - Yahoo Finance
Fate Therapeutics price target lowered to $2.20 by BofA on SLE data - Investing.com Canada
Fate Therapeutics (FATE) Shares Promising Data on FT819 for Lupus Treatment | FATE Stock News - GuruFocus
Fate Therapeutics Announces Updated Clinical Data for FT819 Off-the-shelf CAR T-cell Product Candidate Demonstrating Durability of Drug-free Remission for Severe Lupus Nephritis at EULAR 2025 Congress - The Manila Times
Fate Therapeutics Reports Promising Clinical Data for FT819 in Treating Severe Lupus Nephritis at EULAR 2025 - Nasdaq
Fate’s FT819 shows promising results in lupus patients - Investing.com
Breakthrough: Fate's Off-the-Shelf CAR T-Cell Shows 100% Response Rate in Severe Lupus Patients - Stock Titan
Squarepoint Ops LLC Purchases 20,805 Shares of Fate Therapeutics, Inc. (NASDAQ:FATE) - Defense World
Bank of America Corp DE Sells 550,066 Shares of Fate Therapeutics, Inc. (NASDAQ:FATE) - Defense World
Cantor Fitzgerald Comments on FATE FY2026 Earnings - Defense World
Top Cancer Stocks to Supercharge Your 2025 Portfolio - Yahoo Finance
Two Sigma Investments LP Cuts Stock Holdings in Fate Therapeutics, Inc. (NASDAQ:FATE) - Defense World
Jane Street Group LLC Has $51,000 Holdings in Fate Therapeutics, Inc. (NASDAQ:FATE) - Defense World
Millennium Management LLC Increases Position in Fate Therapeutics, Inc. (NASDAQ:FATE) - Defense World
Ameriprise Financial Inc. Sells 72,581 Shares of Fate Therapeutics, Inc. (NASDAQ:FATE) - Defense World
Public Employees Retirement System of Ohio Sells 46,100 Shares of Fate Therapeutics, Inc. (NASDAQ:FATE) - Defense World
Fate Therapeutics Inc (NASDAQ:FATE) Price Forecast For The Next 12 Months Is Set At 3. - Marketing Sentinel
ProShare Advisors LLC Has $56,000 Stake in Fate Therapeutics, Inc. (NASDAQ:FATE) - Defense World
Fate Therapeutics Stock Draws Investor Attention After FDA Grants Special Designation To Its CAR T-Cell Therapy: Retail Stays Optimistic - MSN
Fate Therapeutics appoints new board member By Investing.com - Investing.com South Africa
Fate Therapeutics Appoints Matthew Abernethy to Board of Directors, Timothy P. Coughlin Steps Down - Nasdaq
Fate Therapeutics appoints new board member - Investing.com
Fate Therapeutics Appoints Matthew Abernethy, M.B.A., to its Board of Directors - GlobeNewswire
Fate Therapeutics Approves Key Proposals at Annual Meeting - TipRanks
Fate Therapeutics to present lupus treatment data at EULAR 2025 By Investing.com - Investing.com South Africa
Fate Therapeutics to present lupus treatment data at EULAR 2025 - Investing.com Australia
Fate Therapeutics, Inc. (FATE) Highlights Next-Gen iPSC Therapies for Autoimmune Diseases - Insider Monkey
Prime Mining: Expanding a High-Grade Gold and Silver Resource in Mexico - The Globe and Mail
Fate Therapeutics Announces Phase 1 Data Presentation of FT819 Off-the-Shelf CAR T-cell Product Candidate for SLE at EULAR 2025 Congress - The Manila Times
Viridian Metals: Targeting Critical Copper Discoveries in Newfoundland - The Globe and Mail
Fate Therapeutics Announces Phase 1 Data Presentation of - GlobeNewswire
Fate Therapeutics Announces Phase 1 Data Presentation of FT819 Off-the-Shelf CAR T-cell Product Candidate for SLE at EULAR 2025 Congress - GlobeNewswire Inc.
Northern Trust Corp Cuts Stock Holdings in Fate Therapeutics, Inc. (NASDAQ:FATE) - Defense World
Fate Therapeutics, Inc. (NASDAQ:FATE) Given Consensus Rating of “Hold” by Analysts - Defense World
Fate Therapeutics’ SWOT analysis: stock outlook amid clinical progress By Investing.com - Investing.com Canada
Fate Therapeutics’ SWOT analysis: stock outlook amid clinical progress - Investing.com
BNP Paribas Financial Markets Raises Holdings in Fate Therapeutics, Inc. (NASDAQ:FATE) - Defense World
Fate Therapeutics Reports Q1 2025 Financial Results - TipRanks
Price T Rowe Associates Inc. MD Cuts Stock Position in Fate Therapeutics, Inc. (NASDAQ:FATE) - Defense World
StockNews.com Upgrades Fate Therapeutics (NASDAQ:FATE) to Hold - Defense World
Barclays Cuts Fate Therapeutics (NASDAQ:FATE) Price Target to $2.00 - Defense World
Wedbush Predicts Increased Earnings for Fate Therapeutics - Defense World
What is Leerink Partnrs’ Estimate for FATE Q2 Earnings? - Defense World
Fate Therapeutics' Q1 Earnings & Revenues Beat, Pipeline in Focus - MSN
Needham & Company LLC Reiterates “Hold” Rating for Fate Therapeutics (NASDAQ:FATE) - Defense World
Fate Therapeutics First Quarter 2025 Earnings: Beats Expectations - Yahoo Finance
Fate Therapeutics (FATE) Faces Significant Price Target Reductio - GuruFocus
1.45%
0.86%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):